Sunil Sachdeva has offloaded 1 million shares of Medanta, the Global Health Limited company, at an average price of ₹1,225 per share.

HDFC Mutual Fund acquired a significant stake of approximately Rs. 122.5 crore in Global Health, with each share purchased at Rs. 1,225. This move followed the company's impressive Q4FY26 profit after tax growth of 39.7%. Consequently, Global Health shares increased by 1% on the National Stock Exchange (NSE), reaching Rs. 1,249.

Global Health, operator of Medanta hospital, aims to boost growth through expansion, increasing bed capacity by 13% by FY27 at an estimated investment of ₹4,500 crores. This growth strategy will be primarily funded by internal resources and strategic debt, aiming for a total bed count of 6,855 beds by FY30.

Global Health's Q4 earnings reveal a 25% revenue increase and a significant 42% jump in profit, yet the EBITDA growth of 9% indicates mounting pressure on margins. The company's CEO and Chairman have addressed these concerns in a discussion about the outlook for the future.

Global Health is expanding its capacity by adding around 600-700 additional hospital beds, aiming to reach a total of 7,000 beds over the next few years, as a result of new regulations.

Global Health's Q4 revenues increased by 25% year-on-year, but the margin dropped to 21%, according to recent reports. Medanta CEO, Pankaj Sahni, attributes this squeeze in profits to certain underlying factors, as detailed in a recent interview.

Global Health plans to invest ₹4,500 crores over the next 3-4 years to expand its bed capacity by 3,200, targeting substantial revenue growth.

Medanta's revenue increased by 20% in the fiscal year 2026, reaching ₹45,089 million. The company saw an 18.6% rise in EBITDA excluding Noida, with a significant expansion of 20.5% in bed capacity, adding 623 beds across its facilities. Profit after tax (PAT) rose by 15.1% to ₹5,541 million, driven by strong growth in outpatient and inpatient volumes.

Global Health reported a significant 42% increase in Q4 profits to ₹143.9 crore and a 24.5% revenue growth to ₹1,159 crore year-on-year. However, the EBITDA margin declined from 24% to 21%. A proposed final dividend of ₹0.50 per share was announced, with shares ending at ₹1,210.30, marking a 1.2% increase.

Global Health's Q4 EBITDA increased by approximately 7% year-over-year, reaching INR 2.4 billion. However, the profit margin dropped slightly from 24.1% to 21%.

Global Health Ltd experienced a significant block deal of approximately $58 million on the National Stock Exchange, with the transaction involving nearly 350,000 shares priced around INR 1,222.8 each.

Global Health Ltd's skyrocketing valuation now categorized as 'very expensive,' potentially increasing investment risks due to higher prices. For hospital sector investors, positive operational returns are evident from P/E and P/BV ratios, signaling a promising market outlook.

Global Health Limited will review its financial year 2026 results during a board meeting on May 14th, 2026. Shareholders should expect a final dividend recommendation to be announced then, along with the temporary closure of trading windows for 48 hours following the results announcement.

Global Health Ltd has announced its plan to acquire a 79-bed cancer hospital in Indore for approximately INR 30 crore. This move aims to strengthen their oncology services, with funding coming from internal resources and debt.

HSBC has increased its price target for Global Health to ₹1,120, reflecting strong quarterly growth in Q4FY26. The growth is driven by an increase in elective procedures, capital expenditure expansion, and margin pressure from new units.